Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Completed NCT05362903

A Non-interventional Implementation Study to Evaluate Treatment With Inclisiran (Leqvio®) and Other Lipid Lowering Treatments in a Real-world Setting

Conditions: Hypercholesterolemia

Sex: All
Ages: 18 Years – 100 Years
Healthy volunteers: No
Enrollment: 1868
Sponsor: Novartis Pharmaceuticals

Location: Novartis Investigative Site Freudenstadt Baden-Wurttemberg

Summary

This was a multicenter, non-randomized, non-interventional three-cohort study with prospective collection of primary data of treatment with newly initiated oral lipid lowering treatment on top of a statin (Oral LLT cohort), newly initiated Inclisiran (Inclisiran cohort) and newly initiated Inclisiran on top of lipid apheresis (Apheresis plus Inclisiran cohort) in routine clinical care. All procedures, treatment adaptions and laboratory assessments were part of clinical routine and conducted independent of this study.

Eligibility Criteria

Inclusion Criteria: 1. Patients who provide written informed consent to participate in the study 2. Male or female patients ≥ 18 years of age 3. Oral LLT Cohort: Patients with documented ASCVD newly initiated on an oral lipid lowering treatment on top of a statin (e.g. ezetimibe, bempedoic acid, cholestyraimin) or new oral LLT alone in case of statin intolerance or contraindication 4. Inclisiran Cohort: Patients newly initiated on Inclisiran fulfilling the restricted reimbursement criteria or individual access requirements who are not at LDL-C goal as per their CV risk as recommended in the 2019 EAS/ESC guidelines (Mach et al., 2020). At least 60% of the documented patients must be PCSK9-inhibitor naive 5. Apheresis plus Inclisiran Cohort: Patients with Inclisiran on top of regular weekly or bi-weekly lipoprotein apheresis (LDL-C or LP(a)). Exclusion Criteria: 1. Oral LLT Cohort: Patients who receive a PCSK9-mAB or other PCSK9-targeted therapy 2. Inclisiran Cohort: current or previous PCSK9-targeted treatment 3. Contraindication for Inclisiran according to the SmPC 4. Patients who have received Inclisiran previously 5. Patients with homozygous FH 6. Any underlying known disease, or surgical, physical, or medical condition that, in the opinion of the investigator (or delegate) might interfere with interpretation of the clinical study results. 7. Simultaneous or planned participation in an interventional research study

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05362903). StuddyBuddy aggregates publicly available trial information.